Purchase this article with an account.
P. A. Campochiaro, S. M. Shah, G. Hafiz, E. Quinlan, I. Zimmer-Galler, Q. D. Nguyen, D. V. Do, H. Ying, J. U. Sung, Wilmer Retinal Research Group; Ranibizumab for Macular Edema Due to Retinal Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1545.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effects of multiple injections of 0.3 and 0.5mg of ranibizumab on macular edema in patients with retinalvein occlusions.
Patients with macular edema due to central (CRVO, n=20) or branchretinal vein occlusion (BRVO, n=20) are being randomized 1:1to receive 3 monthly injections of 0.5 or 0.3 mg of ranibizumab.Primary outcome is change in visual acuity from baseline at3 months. Secondary outcomes are change in visual acuity frombaseline at 0.25, 1, 2, 4 and 6 months, and change in central1 mm foveal thickness (FT) at all of the above time points.
Twelve patients with BRVO and 14 with CRVO have been randomized.Interim results without regard to treatment assignment, whichis unknown, are:
Three intravitreous injections of ranibizumab have been well-toleratedand regardless of dose, preliminary data suggest overall improvementsin VA and foveal thickness. It will be important to determineif there are differences between the treatment groups.
This PDF is available to Subscribers Only